Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…
An antibody that targets a naturally occurring modified form of alpha-synuclein, a protein that forms into toxic clumps in the brain of people with Parkinson’s, delays its buildup and spread in vivo in a mouse model of the disease. This modified form of nitrated alpha-synuclein is being explored by…
A metabolite called M324 of the cancer medicine rucaparib is able to reduce the abnormal accumulation of alpha-synuclein protein in nerve cells derived from people with Parkinson’s disease, showing its potential for treating the neurodegenerative disorder, according to a new study. Metabolites are molecules that result from the biochemical…
Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…
Led by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an international group of patients, researchers, and industry leaders has proposed a framework for defining and staging Parkinson’s disease based on its underlying biology rather than by hallmark disease symptoms. Called the neuronal alpha-synuclein disease integrated…
Prasinezumab is an investigational antibody against alpha-synuclein, a protein that builds up into toxic clumps in Parkinson’s disease, that is being developed as an intravenous (into-the-vein) infusion to slow the progression of Parkinson’s.
Scientists at Purdue University are advancing in lab studies multiple small molecule compounds aiming to prevent the protein aggregation associated with Parkinson’s, Alzheimer’s, and type 2 diabetes, and to safely get rid of existing clumps. Protein aggregation is the term for when proteins — usually abnormal or misfolded…
Phosphorylated alpha-synuclein, a modified form of the protein that forms toxic clumps in the brains of people with Parkinson’s disease and related disorders, appears to play an important role in the normal function of nerve cells, a study shows. When it’s modified, alpha-synuclein binds…
A protein called NEMO can dock to misfolded forms of alpha-synuclein — the protein whose toxic aggregates damage and kill nerve cells in Parkinson’s disease — sending them off for recycling in cellular structures called lysosomes, a study reports. But problems with this waste disposal process can lead to…
Alpha-synuclein — the protein that forms toxic clumps in the brains of people with Parkinson’s disease — may travel from enteroendocrine cells lining the gut to the brain through the vagus nerve, according to a study aiming to build on previous evidence of a gut-brain axis in Parkinson’s.
Get regular updates to your inbox.
